Scribe Therapeutics Inc (SCTX)

$28.67 -2.14 (-6.95%)
Market Cap 542.78M
Revenue (ttm) 51.17M
Net Income (ttm) -21.81M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -42.62%
Debt to Equity Ratio 0.00
Volume 148,100
Avg Vol N/A
Day's Range N/A - N/A
Shares Out 18.93M
Stochastic %K 13%
Beta N/A
Analysts Strong Sell
Price Target $57.00

Company Profile

Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. The company offers STX-1150 designed to be a single-course in vivo epigenetic silencing treatment targeting the PCSK9 gene; STX-1200 is CRISPR-based gene editing program that aims to offer a permanent solution for patients with eleva...

Industry: Biotechnology
Sector: Healthcare
Phone: 510 626 8587
Address:
1150 Marina Village Pkwy, Alameda, United States
Wolfman5960
Wolfman5960 Sep. 6 at 4:33 PM
$SCTX Scribe reported earnings and corporate highlights on September 2nd: https://investors.scribetx.com/news-releases/news-release-details/scribe-therapeutics-reports-second-quarter-2026-financial Also on Friday Novartis/Ionis reported that their LP(a) CVOT trial failed. Ionis, Novartis, and Amgen stocks took a hit afterhours Friday. Amgen's LP(a) CVOT will read out in 2028. Scribe has some investor conferences this month so we'll see if they comment on the Novartis trial failure and how they plan to proceed with their own LP(a) program. Article on the Novartis trial failure if anyone is interested in more details: https://www.fiercebiotech.com/biotech/novartis-lpa-drug-fails-lower-cardiovascular-risk-closely-watched-ph-3-trial
0 · Reply
Rkramden60
Rkramden60 Sep. 3 at 3:54 PM
$SCTX sleeper
0 · Reply
Merlintrader
Merlintrader Sep. 3 at 12:53 PM
Scribe Therapeutics ($SCTX) Stock Hub: a CRISPR Epigenetic Silencer Reaches the Clinic With Cash Into 2029 https://www.merlintrader.com/scribe-therapeutics-sctx-stock-hub/
0 · Reply
Greenspam
Greenspam Sep. 2 at 4:20 PM
$SCTX Extremely
0 · Reply
Rkramden60
Rkramden60 Sep. 2 at 2:48 PM
$SCTX let's go!!!
0 · Reply
Wolfman5960
Wolfman5960 Sep. 1 at 8:40 PM
$SCTX Scribe will be presenting at the following upcoming conferences: Wells Fargo Healthcare Conference: Sept. 9th, 8:00 am ET H.C. Wainwright Conference: Sept. 15th (no time stated currently) Cell & Gene Meeting on the Mesa: Oct 5th, 5:15 pm MT https://investors.scribetx.com/news-releases/news-release-details/scribe-therapeutics-participate-upcoming-investor-conferences-0
0 · Reply
Walkerswealth
Walkerswealth Aug. 31 at 1:00 PM
$SCTX HC Wainright initiates with a BUY - target price $60.
0 · Reply
IPO_Candy
IPO_Candy Aug. 28 at 4:06 PM
$SCTX Sold all this at $40 and bought back some below $30. I put some of our process tips together here: https://www.ipocandy.com/anatomy-of-the-coverage-trade/
1 · Reply
johnrivers0110
johnrivers0110 Aug. 28 at 3:12 PM
$FNGR 😈 Ive also opened shorts on the following stocks… you should do the same👇 $QNRX short opened at .62🩸 $SCTX short opened at 34.05 🩸 $SWVL open short at 2.70🩸 $NCPL open short at .65🩸 I will take all my profits from shorting these stocks and buy any dip on $FNGR 🐇🚀🚀🚀 before it rockets to 300% The Matrix 🔺 The FiB 🔺
3 · Reply
dmeph
dmeph Aug. 25 at 9:24 AM
$SCTX overextended, due for a red day
0 · Reply
Latest News on SCTX
Scribe Therapeutics reports Q2 EPS ($2.62), consensus ($3.72)

2026-09-02T20:30:15.000Z - 5 days ago

Scribe Therapeutics reports Q2 EPS ($2.62), consensus ($3.72)

Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Sep 2, 2026, 4:05 PM EDT - 5 days ago

Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Scribe Therapeutics Earnings release: Q2 2026

Sep 2, 2026, 4:00 PM EDT - 5 days ago

Scribe Therapeutics Earnings release: Q2 2026

Scribe Therapeutics Quarterly report: Q2 2026

Sep 2, 2026, 4:00 PM EDT - 5 days ago

Scribe Therapeutics Quarterly report: Q2 2026

Scribe Therapeutics Slides: Investor presentation

Sep 2, 2026, 7:00 AM EDT - 5 days ago

Scribe Therapeutics Slides: Investor presentation

Scribe Therapeutics to Participate in Upcoming Investor Conferences

Sep 1, 2026, 8:00 AM EDT - 6 days ago

Scribe Therapeutics to Participate in Upcoming Investor Conferences

Scribe Therapeutics initiated with a Buy at H.C. Wainwright

2026-08-31T10:15:32.000Z - 7 days ago

Scribe Therapeutics initiated with a Buy at H.C. Wainwright

Leerink starts Scribe Therapeutics at Outperform on X-editor platform

2026-08-18T17:10:10.000Z - 20 days ago

Leerink starts Scribe Therapeutics at Outperform on X-editor platform

Scribe Therapeutics initiated with an Outperform at Leerink

2026-08-18T10:10:25.000Z - 20 days ago

Scribe Therapeutics initiated with an Outperform at Leerink

Scribe Therapeutics initiated with a Buy at Guggenheim

2026-08-18T09:35:06.000Z - 20 days ago

Scribe Therapeutics initiated with a Buy at Guggenheim

Scribe Therapeutics initiated with an Overweight at Wells Fargo

2026-08-18T09:05:07.000Z - 20 days ago

Scribe Therapeutics initiated with an Overweight at Wells Fargo

Scribe Therapeutics initiated with Early-Stage Biotech at Goldman Sachs

2026-08-18T08:15:11.000Z - 20 days ago

Scribe Therapeutics initiated with Early-Stage Biotech at Goldman Sachs

Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters' Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement

Jul 27, 2026, 4:05 PM EDT - 6 weeks ago

Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters' Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement

Opening Day: Scribe Therapeutics makes strong trading debut

2026-07-27T15:25:46.000Z - 6 weeks ago

Opening Day: Scribe Therapeutics makes strong trading debut

BCCQ BSP CCCT CGCF ECR FDMM FWAC

Scribe Therapeutics opens at $25, IPO priced at $15 per share

2026-07-24T16:00:48.000Z - 6 weeks ago

Scribe Therapeutics opens at $25, IPO priced at $15 per share

Scribe Therapeutics indicated to open at $25, IPO priced at $15 per share

2026-07-24T15:25:24.000Z - 6 weeks ago

Scribe Therapeutics indicated to open at $25, IPO priced at $15 per share

Scribe Therapeutics indicated to open at $29.20, IPO priced at $15 per share

2026-07-24T15:00:12.000Z - 6 weeks ago

Scribe Therapeutics indicated to open at $29.20, IPO priced at $15 per share

Scribe Therapeutics 8.58M share IPO priced at $15.00

2026-07-24T10:05:34.000Z - 6 weeks ago

Scribe Therapeutics 8.58M share IPO priced at $15.00

Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering

Jul 23, 2026, 9:08 PM EDT - 6 weeks ago

Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering

Scribe Therapeutics IPO Registration Document (S-1)

Jul 2, 2026, 4:46 PM EDT - 2 months ago

Scribe Therapeutics IPO Registration Document (S-1)

Cardiovascular diseases biotech Scribe Therapeutics files for a $75 million IPO

Jul 2, 2026, 1:30 PM EDT - 2 months ago

Cardiovascular diseases biotech Scribe Therapeutics files for a $75 million IPO

Wolfman5960
Wolfman5960 Sep. 6 at 4:33 PM
$SCTX Scribe reported earnings and corporate highlights on September 2nd: https://investors.scribetx.com/news-releases/news-release-details/scribe-therapeutics-reports-second-quarter-2026-financial Also on Friday Novartis/Ionis reported that their LP(a) CVOT trial failed. Ionis, Novartis, and Amgen stocks took a hit afterhours Friday. Amgen's LP(a) CVOT will read out in 2028. Scribe has some investor conferences this month so we'll see if they comment on the Novartis trial failure and how they plan to proceed with their own LP(a) program. Article on the Novartis trial failure if anyone is interested in more details: https://www.fiercebiotech.com/biotech/novartis-lpa-drug-fails-lower-cardiovascular-risk-closely-watched-ph-3-trial
0 · Reply
Rkramden60
Rkramden60 Sep. 3 at 3:54 PM
$SCTX sleeper
0 · Reply
Merlintrader
Merlintrader Sep. 3 at 12:53 PM
Scribe Therapeutics ($SCTX) Stock Hub: a CRISPR Epigenetic Silencer Reaches the Clinic With Cash Into 2029 https://www.merlintrader.com/scribe-therapeutics-sctx-stock-hub/
0 · Reply
Greenspam
Greenspam Sep. 2 at 4:20 PM
$SCTX Extremely
0 · Reply
Rkramden60
Rkramden60 Sep. 2 at 2:48 PM
$SCTX let's go!!!
0 · Reply
Wolfman5960
Wolfman5960 Sep. 1 at 8:40 PM
$SCTX Scribe will be presenting at the following upcoming conferences: Wells Fargo Healthcare Conference: Sept. 9th, 8:00 am ET H.C. Wainwright Conference: Sept. 15th (no time stated currently) Cell & Gene Meeting on the Mesa: Oct 5th, 5:15 pm MT https://investors.scribetx.com/news-releases/news-release-details/scribe-therapeutics-participate-upcoming-investor-conferences-0
0 · Reply
Walkerswealth
Walkerswealth Aug. 31 at 1:00 PM
$SCTX HC Wainright initiates with a BUY - target price $60.
0 · Reply
IPO_Candy
IPO_Candy Aug. 28 at 4:06 PM
$SCTX Sold all this at $40 and bought back some below $30. I put some of our process tips together here: https://www.ipocandy.com/anatomy-of-the-coverage-trade/
1 · Reply
johnrivers0110
johnrivers0110 Aug. 28 at 3:12 PM
$FNGR 😈 Ive also opened shorts on the following stocks… you should do the same👇 $QNRX short opened at .62🩸 $SCTX short opened at 34.05 🩸 $SWVL open short at 2.70🩸 $NCPL open short at .65🩸 I will take all my profits from shorting these stocks and buy any dip on $FNGR 🐇🚀🚀🚀 before it rockets to 300% The Matrix 🔺 The FiB 🔺
3 · Reply
dmeph
dmeph Aug. 25 at 9:24 AM
$SCTX overextended, due for a red day
0 · Reply
Gaidin
Gaidin Aug. 24 at 6:37 PM
$SCTX Best trade for me so far this year.
1 · Reply
CDMO
CDMO Aug. 24 at 5:55 PM
$SCTX ahhh stop it! Should have just bought this
0 · Reply
Rmccall
Rmccall Aug. 24 at 2:01 PM
$SLS lucky I have $SCTX on days like this. This will be green by EOD. Go fukers!
0 · Reply
SocioCobb
SocioCobb Aug. 24 at 11:32 AM
$SCTX Bang x 2!!!
0 · Reply
Greenspam
Greenspam Aug. 20 at 4:32 PM
$SCTX Extremely
0 · Reply
Wolfman5960
Wolfman5960 Aug. 20 at 4:15 PM
$SCTX Good article about Scribe on BioSpace from today: https://www.biospace.com/business/scribes-early-stage-ipo-standout-defies-biotechs-derisking-trend
0 · Reply
Greenspam
Greenspam Aug. 20 at 4:14 PM
$SLS and $SCTX
1 · Reply
CDMO
CDMO Aug. 20 at 3:13 PM
$SCTX lol up 50% since post
0 · Reply
Wolfman5960
Wolfman5960 Aug. 20 at 3:02 PM
$SCTX Rough day for the biotech sector, but this is going strong. Not surprised since there's a limited amount of shares available and the quiet period ending with high analyst price targets. Scribe should raise some additional capital at these levels, but I doubt they'll want to dilute more before the lockup period expires in January. Looking forward to seeing the upcoming Novartis/Ionis LP(a) CVOT readout and how the PCSK9 data plays out next year.
0 · Reply
MaverikIT
MaverikIT Aug. 20 at 2:42 PM
@Jblack500 @IsabellaDC @BustaCapital @WAJeff @cynicaloptimist @No_Face_character $SCTX +5.35
0 · Reply
MaverikIT
MaverikIT Aug. 20 at 2:34 PM
@Jblack500 @IsabellaDC @BustaCapital @WAJeff @cynicaloptimist @No_Face_character $SCTX +3.45 tagging on $TGTX AMLX AUPH ETON
1 · Reply
D0n3da
D0n3da Aug. 19 at 4:27 PM
$SCTX so this company with only an ongoing Ph1 outside the US, miles behind Verve / Lilly, with a massive COI that prevents Lilly from getting involved with their LDL-C drug unless they outright buy them, is 1/3 the MC of intellia with the first in vivo BLA coming up. Joke
0 · Reply